Evidence map›Paper›PMID 35897711›Full record

ReviewInternational journal of molecular sciences2022

Clinical Tear Fluid Proteomics-A Novel Tool in Glaucoma Research.

Janika Nättinen, Ulla Aapola, Praveena Nukareddy, Hannu Uusitalo

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07690397 (GLAUCO-TECH Study), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07690397 phase4active not recruitingnot on this mapstarted 2026, after this paper: background citation

GLAUCO-TECH Study: Safety & Efficacy of Preservative-free vs. Preserved Dorzolamide-Timolol-Brimonidine. Impact on the Ocular Surface, Glaucoma Progression, Tear Proteomics, and AI/Chatbot-led Patient Follow-up.

TypeinterventionalSponsorTecnoquimicasRan2026 to 2027Enrolled140ConditionsPrimary Open-Angle Glaucoma (POAG), Ocular HypertensionArmsPreservative-free dorzolamide-timolol-brimonidine combination, Preservative dorzolamide-timolol-brimonidine combination
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Tear fluid database: a reference website for tear fluid proteomics.Database : the journal of biological databases and curation · 2026
    Article
  5. Article
  6. Dried Spot Paradigm: Problems and Prospects in Proteomics.International journal of molecular sciences · 2025
    Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Unraveling the Intraday Variations in the Tear Fluid Proteome.Investigative ophthalmology & visual science · 2024
    Article
  14. Liquid Biopsy Proteomics in Ophthalmology.Journal of proteome research · 2024
    Review
  15. Tear nanoDSF Denaturation Profile Is Predictive of Glaucoma.International journal of molecular sciences · 2023
    Article
  16. Posttranslational modifications of proteins in diseased retina.Frontiers in cellular neuroscience · 2023
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Janika NättinenEye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Ulla AapolaEye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.ORCID 0000-0001-7691-3170
Praveena NukareddyEye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Hannu UusitaloEye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Tampere University · FI

Funding

Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital NAElsemay Björn Foundation NAGlaukoomatukisäätiö Lux NAPaulo Foundation NA
6 · The paper itself

Abstract

Tear fluid forms the outermost layer of the ocular surface and its characteristics and composition have been connected to various ocular surface diseases. As tear proteomics enables the non-invasive investigation of protein levels in the tear fluid, it has become an increasingly popular approach in ocular surface and systemic disease studies. Glaucoma, which is a set of multifactorial diseases affecting mainly the optic nerve and retinal ganglion cells, has also been studied using tear proteomics. In this condition, the complete set of pathophysiological changes occurring in the eye is not yet fully understood, and biomarkers for early diagnosis and accurate treatment selection are needed. More in-depth analyses of glaucoma tear proteomics have started to emerge only more recently with the implementation of LC-MS/MS and other modern technologies. The aim of this review was to examine the published data of the tear protein changes occurring during glaucoma, its topical treatment, and surgical interventions.

Indexed as

GlaucomaProteomicsChromatography, LiquidEye ProteinsHumansTandem Mass SpectrometryTearsEye Proteinsglaucomaproteomicstear fluid

Identifiers

PMID35897711
PMCPMC9331117
OpenAlexW4287010044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.